Loading
A phase 2 trial of Sonrotoclax and Zanubrutinib in chronic lymphocytic leukaemia, run by BeOne Medicines, active and no longer recruiting.
A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia is a phase 2 interventional study registered as NCT06637501 by BeOne Medicines, with 94 participants enrolled, started 2024-11-14 and due to reach its primary completion in 2026-11. Interventions recorded: Sonrotoclax and Zanubrutinib.
Shares Sonrotoclax, Zanubrutinib, BCL-2 inhibitors, Chronic lymphocytic leukaemia, first treatment and the tag pipeline.
Shares Sonrotoclax, Zanubrutinib, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene) and the tag pipeline.
Shares Sonrotoclax, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene), Chronic lymphocytic leukaemia and the tag pipeline.
Shares Sonrotoclax, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene), Small-molecule kinase inhibitors and the tag pipeline.
Shares Sonrotoclax, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene), Chronic lymphocytic leukaemia and the tag pipeline.
Shares BCL-2 inhibitors, Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Zanubrutinib, BeOne Medicines (formerly BeiGene), Small-molecule kinase inhibitors and the tag pipeline.
Shares BCL-2 inhibitors, Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.